Post-Transplant Disease Recurrence in Pediatric PSC

Area of Science:

• Pediatric gastroenterology and hepatology
• Transplant surgery
• Immunology

Background:

• Primary sclerosing cholangitis (PSC) is a chronic liver disease.
• Liver transplantation is a treatment for end-stage PSC.
• Recurrence of PSC post-transplant is a known complication.

Purpose of the Study:

• To review current knowledge on recurrent PSC (rPSC) in pediatric liver transplant recipients.
• To identify risk factors and outcomes associated with rPSC.
• To explore current and potential therapeutic strategies for rPSC.

Main Methods:

• Literature review of studies on pediatric liver transplantation for PSC.
• Analysis of reported incidence, risk factors, and outcomes of rPSC.
• Evaluation of existing and emerging treatment options for rPSC.

Main Results:

• Recurrent PSC affects 16% of pediatric liver transplant recipients for PSC.
• Median onset of rPSC is 38 months post-transplant.
• Potential risk factors include younger age, overlap syndrome, IBD, and thymoglobulin induction.
• rPSC negatively impacts graft survival and quality of life.
• Limited effective preventive and therapeutic options are available.

Conclusions:

• Recurrent PSC is a significant complication following pediatric liver transplantation for PSC.
• Further research is needed to elucidate risk factors and develop effective interventions.
• Current treatments like ursodeoxycholic acid and vancomycin have unproven long-term efficacy.